XML 202 R169.htm IDEA: XBRL DOCUMENT
v3.23.1

Gains (losses) from operating activities in the statement of income of expenses, included according to their nature - Revenue by Geographic Location (Details) - USD ($) $ in Thousands | 12 Months Ended
--- | ---
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020
Statement [Line Items] |  |  |
Revenue | $ 10,710,578 | $ 2,862,315 | $ 1,817,191
Specialty plant nutrition |  |  |
Statement [Line Items] |  |  |
Revenue | 1,172,334 | 908,815 | 701,688
Iodine and derivatives |  |  |
Statement [Line Items] |  |  |
Revenue | 754,339 | 437,931 | 334,657
Lithium and derivatives |  |  |
Statement [Line Items] |  |  |
Revenue | 8,152,939 | 936,121 | 383,373
Potassium |  |  |
Statement [Line Items] |  |  |
Revenue | 437,180 | 416,592 | 209,294
Industrial chemicals |  |  |
Statement [Line Items] |  |  |
Revenue | 165,200 | 132,011 | 160,608
Other |  |  |
Statement [Line Items] |  |  |
Revenue | 28,586 | 30,845 | 27,571
Chile |  |  |
Statement [Line Items] |  |  |
Revenue | 223,148 | 219,648 | 153,745
Chile | Specialty plant nutrition |  |  |
Statement [Line Items] |  |  |
Revenue | 128,829 | 136,523 | 100,353
Chile | Iodine and derivatives |  |  |
Statement [Line Items] |  |  |
Revenue | 1,523 | 1,538 | 1,234
Chile | Lithium and derivatives |  |  |
Statement [Line Items] |  |  |
Revenue | 1,854 | 901 | 399
Chile | Potassium |  |  |
Statement [Line Items] |  |  |
Revenue | 64,409 | 50,573 | 23,963
Chile | Industrial chemicals |  |  |
Statement [Line Items] |  |  |
Revenue | 1,199 | 4,125 | 4,059
Chile | Other |  |  |
Statement [Line Items] |  |  |
Revenue | 25,334 | 25,988 | 23,737
Latin America and the Caribbean |  |  |
Statement [Line Items] |  |  |
Revenue | 339,941 | 326,287 | 159,990
Latin America and the Caribbean | Specialty plant nutrition |  |  |
Statement [Line Items] |  |  |
Revenue | 125,712 | 88,990 | 69,535
Latin America and the Caribbean | Iodine and derivatives |  |  |
Statement [Line Items] |  |  |
Revenue | 16,328 | 10,198 | 10,843
Latin America and the Caribbean | Lithium and derivatives |  |  |
Statement [Line Items] |  |  |
Revenue | 5,275 | 4,905 | 1,597
Latin America and the Caribbean | Potassium |  |  |
Statement [Line Items] |  |  |
Revenue | 179,621 | 214,304 | 72,697
Latin America and the Caribbean | Industrial chemicals |  |  |
Statement [Line Items] |  |  |
Revenue | 11,820 | 7,367 | 4,951
Latin America and the Caribbean | Other |  |  |
Statement [Line Items] |  |  |
Revenue | 1,185 | 523 | 367
Europe |  |  |
Statement [Line Items] |  |  |
Revenue | 932,558 | 482,765 | 380,125
Europe | Specialty plant nutrition |  |  |
Statement [Line Items] |  |  |
Revenue | 196,930 | 179,744 | 145,896
Europe | Iodine and derivatives |  |  |
Statement [Line Items] |  |  |
Revenue | 288,854 | 173,329 | 142,161
Europe | Lithium and derivatives |  |  |
Statement [Line Items] |  |  |
Revenue | 390,832 | 75,674 | 49,719
Europe | Potassium |  |  |
Statement [Line Items] |  |  |
Revenue | 27,275 | 33,948 | 30,029
Europe | Industrial chemicals |  |  |
Statement [Line Items] |  |  |
Revenue | 27,725 | 18,662 | 11,585
Europe | Other |  |  |
Statement [Line Items] |  |  |
Revenue | 942 | 1,408 | 735
North America |  |  |
Statement [Line Items] |  |  |
Revenue | 914,187 | 558,002 | 427,570
North America | Specialty plant nutrition |  |  |
Statement [Line Items] |  |  |
Revenue | 489,327 | 314,895 | 246,737
North America | Iodine and derivatives |  |  |
Statement [Line Items] |  |  |
Revenue | 141,683 | 102,746 | 90,292
North America | Lithium and derivatives |  |  |
Statement [Line Items] |  |  |
Revenue | 151,152 | 50,349 | 25,558
North America | Potassium |  |  |
Statement [Line Items] |  |  |
Revenue | 71,711 | 57,682 | 39,432
North America | Industrial chemicals |  |  |
Statement [Line Items] |  |  |
Revenue | 59,402 | 29,860 | 23,963
North America | Other |  |  |
Statement [Line Items] |  |  |
Revenue | 912 | 2,470 | 1,588
Asia and Others |  |  |
Statement [Line Items] |  |  |
Revenue | 8,300,744 | 1,275,613 | 695,761
Asia and Others | Specialty plant nutrition |  |  |
Statement [Line Items] |  |  |
Revenue | 231,536 | 188,663 | 139,167
Asia and Others | Iodine and derivatives |  |  |
Statement [Line Items] |  |  |
Revenue | 305,951 | 150,120 | 90,127
Asia and Others | Lithium and derivatives |  |  |
Statement [Line Items] |  |  |
Revenue | 7,603,826 | 804,292 | 306,100
Asia and Others | Potassium |  |  |
Statement [Line Items] |  |  |
Revenue | 94,164 | 60,085 | 43,173
Asia and Others | Industrial chemicals |  |  |
Statement [Line Items] |  |  |
Revenue | 65,054 | 71,997 | 116,050
Asia and Others | Other |  |  |
Statement [Line Items] |  |  |
Revenue | $ 213 | $ 456 | $ 1,144

X
- Definition The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2022-03-24 -Paragraph 28 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_a&doctype=Standard -URIDate 2022-03-24 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2022-03-24 -Paragraph 23 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_a&doctype=Standard -URIDate 2022-03-24 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2022-03-24 -Paragraph 32 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_32&doctype=Standard -URIDate 2022-03-24 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2022-03-24 -Paragraph 33 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_33_a&doctype=Standard -URIDate 2022-03-24 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2022-03-24 -Paragraph 34 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard -URIDate 2022-03-24 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 5 -IssueDate 2022-03-24 -Paragraph 33 -Subparagraph b -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_33_b_i&doctype=Standard -URIDate 2022-03-24 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2022-03-24 -Paragraph B12 -Subparagraph b -Clause v -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B -URIDate 2022-03-24 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Name IFRS -Number 12 -IssueDate 2022-03-24 -Paragraph B10 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B -URIDate 2022-03-24 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2022-03-24 -Paragraph 82 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_a&doctype=Standard -URIDate 2022-03-24 Reference 10: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 1 -IssueDate 2022-03-24 -Paragraph 103 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_103&doctype=Standard -URIDate 2022-03-24 Reference 11: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 1 -IssueDate 2022-03-24 -Paragraph 102 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_102&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_Revenue
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Statement + References No definition available. + Details
Name: | sqm_StatementLineItems
Namespace Prefix: | sqm_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sqm_SpecialtyPlantNutritionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sqm_IodineAndDerivativesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sqm_LithiumAndDerivativesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sqm_PotassiumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sqm_IndustrialChemicalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sqm_OthersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=sqm_ChileCountryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=sqm_LatinAmericaAndCaribbeanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=sqm_AjayEuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=sqm_AjayNorthAmericaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=sqm_AsiaAndOthersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |